The approval follows results from the Phase 3 UP-AA clinical program, which evaluated the efficacy of 15 mg and 30 mg doses of upadacitinib. Participants receiving the treatment demonstrated statistically significant scalp hair regrowth by week 24, as measured by the Severity of Alopecia Tool score. Notably, the drug is the first JAK inhibitor to achieve complete scalp hair regrowth in clinical trials compared to a placebo, while also showing marked improvement in eyebrow and eyelash coverage.

Alopecia areata is an unpredictable autoimmune disease that manifests as everything from isolated bald patches to total loss of body hair. Patients often face a 40% higher risk of developing depression and anxiety compared to the general population. Dr. Roopal Thakkar, AbbVie’s chief scientific officer, noted that the approval offers a critical management tool for a patient community that has historically navigated the disease with limited medical support. Clinical data indicates that the drug’s safety profile remains consistent with its previously established use in other inflammatory conditions, such as atopic dermatitis and rheumatoid arthritis.